Home
Promedior, Inc.

Promedior, Inc. Market Share Analysis for June 2026

promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis.

Industry: N/A

Domainpromedior.com

Year Founded2006

Employees51 - 200

Annual Revenue$100M - $200M

Promedior, Inc.

Promedior, Inc. (including company regionals)

promedior.com

See more website traffic and engagement information

Promedior, Inc. Revenue up to June 2026 is 100M - 200M

revenue generated by Promedior, Inc. top domains

Promedior, Inc. top domains revenue over 3 years

Revenue for Promedior, Inc. top domains

promedior.com100M - 200M

See more with Sales Intelligence

Total visits to Promedior, Inc.'s top domains

Understand Promedior, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Promedior, Inc.'s top domains

Analyze Promedior, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Promedior, Inc.'s top domains

See how Promedior, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Promedior, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Promedior, Inc.

These are the website technologies, by industry, used by Promedior, Inc. top domains

Payment & Currencies (2)

Pound Sterling

Social (2)

Twitter

Mobile (1)

Meta Viewport

News & Signals from Promedior, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsRoche SA acquired Promedior on Feb 1st '20.For Instance, in February 2020, F. Hoffmann-La Roche AG completely acquired Promedior, Inc., a clinical stage biotechnology company.

NewsRoche acquires Promedior for $1.39B.Recent exits have included Roche’s acquisition of Promedior for up to $1.39 billion with an upfront payment of $390 million, and Roche also acquiring the full rights to the Inflazome portfolio of NLRP3 inflammasome inhibitors for €380 million plus milestones.

NewsRoche acquired Promedior for $1.4B on Jan 1st '19.[KATERYNA KON/SCIENCE PHOTO LIBRARY / Getty Images] Roche has agreed to acquire Promedior for up to $1.4 billion, Promedior said today—a year after previous suitor Bristol-Myers Squibb (BMS) opted not to exercise its right to acquire the developer of treatments for fibrotic diseases for $1.25 billion.